Amgen, Myriad Genetics and Vicor offer three different reasons to watch today's session: clinical progress, a planned asset sale and stronger earnings. These continuing October 20 catalysts are listed newest first by announcement time. Prices below are October 20 regular-session closes, not live premarket quotes.
1. Amgen (AMGN): clinical evidence strengthens the opportunity
Amgen's October 20, 09:00 EDT CROSSING results showed tissue remission at week 24 in 68.9% of patients receiving the higher Tezspire dose, versus 3.5% on placebo, alongside improved swallowing symptoms. The findings support a potential additional use for the medicine; they are not approval for eosinophilic esophagitis.
AMGN closed at $438.94, up 3.29%. October 21 Momentum is neutral at 51.1, while the experimental daily model's Up score is 57.2%. Healthcare breadth supported the move on October 20: 361 stocks rose and 105 fell. Watch for a regulatory filing; approval, reimbursement and competition remain hurdles before trial success becomes additional sales.
2. Myriad Genetics (MYGN): a potential balance-sheet reset
The October 20, 08:30 EDT Labcorp agreement announcement confirmed a planned sale of Myriad's prenatal testing business for $210 million cash plus inventory value. Management expects the transaction to strengthen its balance sheet and sharpen its cancer-care focus.
MYGN closed at $5.54, up 31.59%, so substantial optimism is already reflected in the price. Momentum remains bearish at 49.6 and today's model Up score is only 38.7%: positive corporate news does not guarantee another positive session. Closing is expected by early 2027, subject to clearance and other conditions. The next check is management's November 4 explanation of the remaining business and transaction effects.
3. Vicor (VICR): stronger revenue, with royalty risk
Vicor's October 20, 07:00 EDT quarterly results reported revenue of $197.1 million, up 78.5% year over year, with a 68.3% gross margin. Royalty revenue contributed $66.6 million, making its durability an important follow-up question.
VICR closed at $204.14, up 7.06%, but remained 23.61% lower over the past week. Momentum is neutral at 51.9 and today's model Up score is 69.2%. AI infrastructure breadth was mixed: 71 stocks advanced and 80 declined. Watch whether product demand and repeat royalties sustain the stronger earnings; one excellent quarter does not establish a durable trend.
The experimental models correctly called Myriad and Vicor's October 20 direction but missed Amgen's rise. Today's scores remain pending, are not expected percentage gains, and should be weighed alongside fresh business evidence. All three names remain research candidates after substantial price reactions.
Research only, not investment advice.